Get started
Author

Junning Cao

Observed names: J. CAO, J. Cao, J.‐N. Cao, JUN-NING CAO, JUNNING CAO, Jun-Ning Cao, Jun-ning Cao
Observed institutions: Qingdao University, Shanghai Medical College of Fudan University, Fudan University, Chinese PLA General Hospital, Fudan University Shanghai Cancer Center, Affiliated Hospital of Qingdao University, Shanghai East Hospital, Jiangsu Cancer Hospital
ORCID: 0000-0002-3146-9413
Observed ORCID: 0000-0002-3146-9413
OpenAlex ID: A5076296804
A Single-Arm, Multicenter, Phase II Study of Camrelizumab in Relapsed or Refractory Classical Hodgkin Lymphoma
2019 · Yuqin Song, Jianqiu Wu, et al. · Clinical Cancer Research · 150
Lenvatinib plus anti-PD-1 antibodies as conversion therapy for patients with unresectable intermediate-advanced hepatocellular carcinoma: a single-arm, phase II trial
2023 · Wenwen Zhang, Shuang Tong, et al. · Journal for ImmunoTherapy of Cancer · 136
PDF
Hepatitis B virus reactivation in B-cell lymphoma patients treated with rituximab: Analysis from the Asia Lymphoma Study Group
2013 · Seok Jin Kim, Chiun Hsu, et al. · European Journal of Cancer · 123
Safety and efficacy of fruquintinib in patients with previously treated metastatic colorectal cancer: a phase Ib study and a randomized double-blind phase II study
2017 · Rui-Hua Xu, Jin Li, et al. · Journal of Hematology & Oncology · 89
PDF
Extranodal natural killer/T-cell lymphoma involving the gastrointestinal tract: analysis of clinical features and outcomes from the Asia Lymphoma study group
2013 · Seok Jin Kim, Hyun Ae Jung, et al. · Journal of Hematology & Oncology · 85
PDF
A Phase I study of safety and pharmacokinetics of fruquintinib, a novel selective inhibitor of vascular endothelial growth factor receptor-1, -2, and -3 tyrosine kinases in Chinese patients with advanced solid tumors
2016 · Junning Cao, Jian Zhang, et al. · Cancer Chemotherapy and Pharmacology · 74
Interstitial pneumonitis during rituximab-containing chemotherapy for non-Hodgkin lymphoma
2008 · Xin Liu, Xiao-Nan Hong, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 69
Surgery After Conversion Therapy With PD-1 Inhibitors Plus Tyrosine Kinase Inhibitors Are Effective and Safe for Advanced Hepatocellular Carcinoma: A Pilot Study of Ten Patients
2021 · Wenwen Zhang, Bingyang Hu, et al. · Frontiers in Oncology · 65
PDF
Low incidence of hepatitis B virus reactivation during chemotherapy among diffuse large B‐cell lymphoma patients who are HBsAg‐negative/ HBcAb‐positive: a multicenter retrospective study
2010 · Dongmei Ji, Junning Cao, et al. · European Journal Of Haematology · 63
Odronextamab monotherapy in patients with relapsed/refractory diffuse large B cell lymphoma: primary efficacy and safety analysis in phase 2 ELM-2 trial
2025 · Won Seog Kim, Tae Min Kim, et al. · Nature Cancer · 57
PDF
Sugemalimab Monotherapy for Patients With Relapsed or Refractory Extranodal Natural Killer/T-Cell Lymphoma (GEMSTONE-201): Results From a Single-Arm, Multicenter, Phase II Study
2023 · Huiqiang Huang, Rong Tao, et al. · Journal of Clinical Oncology · 53
PDF
Final Analysis of the Phase 2 ELM-2 Study: Odronextamab in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)
2023 · Sabarish Ayyappan, Won Seog Kim, et al. · Blood · 51
Polatuzumab vedotin in previously untreated DLBCL: an Asia subpopulation analysis from the phase 3 POLARIX trial
2023 · Yuqin Song, Yuqin Song, et al. · Blood · 50
Rituximab in combination with CHOP chemotherapy for the treatment of diffuse large B cell lymphoma in China: a 10-year retrospective follow-up analysis of 437 cases from Shanghai Lymphoma Research Group
2011 · Xiaoyang Li, Zhao Liu, et al. · Annals of Hematology · 42
A phase I study of AST1306, a novel irreversible EGFR and HER2 kinase inhibitor, in patients with advanced solid tumors
2014 · Jian Zhang, Junning Cao, et al. · Journal of Hematology & Oncology · 40
PDF
The Oral PI3Kδ Inhibitor Linperlisib for the Treatment of Relapsed and/or Refractory Follicular Lymphoma: A Phase II, Single-Arm, Open-Label Clinical Trial
2023 · Tingyu Wang, Xiuhua Sun, et al. · Clinical Cancer Research · 39
Finotonlimab with chemotherapy in recurrent or metastatic head and neck cancer: a randomized phase 3 trial
2024 · Yuankai Shi, Wei Guo, et al. · Nature Medicine · 36
Blastic Plasmacytoid Dendritic Cell Neoplasm without Cutaneous Lesion at Presentation: Case Report and Literature Review
2012 · Huijie Wang, Junning Cao, et al. · Acta Haematologica · 36
Orelabrutinib for the treatment of relapsed or refractory MCL: a phase 1/2, open-label, multicenter, single-arm study
2023 · Li-Juan Deng, Ke-Shu Zhou, et al. · Blood Advances · 32
PDF
Integrated Single Cell Analysis Reveals An Atlas of Tumor Associated Macrophages in Hepatocellular Carcinoma
2024 · Xinqiang Li, Ruixia Li, et al. · Inflammation · 29
Pharmacokinetics of Osimertinib in Chinese Patients With Advanced NSCLC: A Phase 1 Study
2017 · Hongyun Zhao, Junning Cao, et al. · The Journal of Clinical Pharmacology · 29
Treatment of mantle cell lymphoma in Asia: a consensus paper from the Asian Lymphoma Study Group
2020 · Dok Hyun Yoon, Junning Cao, et al. · Journal of Hematology & Oncology · 27
PDF
Safety and Efficacy of Orelabrutinib Monotherapy in Chinese Patients with Relapsed or Refractory Mantle Cell Lymphoma: A Multicenter, Open-Label, Phase II Study
2019 · Yuqin Song, Yongping Song, et al. · Blood · 27
Chidamide combined with cyclophosphamide, doxorubicin, vincristine and prednisone in previously untreated patients with peripheral T-cell lymphoma
2021 · Lin Gui, Junning Cao, et al. · Chinese Journal of Cancer Research · 26
Cardiotoxicity as indicated by LVEF and troponin T sensitivity following two anthracycline-based regimens in lymphoma: Results from a randomized prospective clinical trial
2016 · Kai Xue, Juan J. Gu, et al. · Oncotarget · 25
Works count: 225
Citation count: 2,115
H-index: 25
I10-index: 46
Year
Topic
Type